For two decades, scientists have been studying how immunotherapies may help treat Alzheimer's disease. The theory is that antibodies might trigger the brain to destroy a kind of protein that clumps in the brain of patients. The clumps are known as beta-amyloid plaques.
Recently, some large clinical trials of that kind of immunotherapy have failed.
An editorial in the New England Journal of Medicine says researchers may be "nearing the end of the amyloid-hypothesis rope."
Dr. Reisa Sperling says not yet, and she speaks with Here & Now's Lisa Mullins.
This segment aired on February 13, 2018.
- Amid Setbacks In Field, Boston Alzheimer's Researcher Forges Ahead With Immunotherapy Trials
- Is Amyloid, The Leading Hypothesis For Treating Alzheimer’s, Played Out? Not So Fast
- Early Clinical Trial